Report of Foreign Issuer (6-k)
April 16 2019 - 4:29PM
Edgar (US Regulatory)
FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For
period ending
16 April
2019
GlaxoSmithKline plc
(Name
of registrant)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or
will
file annual reports under cover Form 20-F or Form
40-F
Form
20-F x Form 40-F
--
Indicate
by check mark whether the registrant by furnishing the
information
contained in this Form is also thereby furnishing the
information
to the Commission pursuant to Rule 12g3-2(b) under the
Securities
Exchange Act of 1934.
Yes
No x
GlaxoSmithKline plc (the '
Company
')
Transaction notification
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Ms E Walmsley
|
b)
|
Position/status
|
Chief Executive Officer
|
c)
|
Initial
notification/amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description of the
financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
b)
|
Nature of the
transaction
|
Increase in interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 11 April 2019 on Ordinary
Shares held in the Company's Deferred Annual Bonus
Plan.
|
c)
|
Price(s) and
volume(s)
|
Price(s)
|
Volume(s)
|
£15.6560
|
908.000
|
£15.6560
|
260.000
|
£15.6560
|
912.000
|
£15.6560
|
260.000
|
d)
|
Aggregated
information
Aggregated
volume
Price
|
2340.000
£15.6560
|
e)
|
Date
of the transaction
|
2019-04-12
|
f)
|
Place of the
transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Dr H Barron
|
b)
|
Position/status
|
Chief Scientific Officer and President, R&D
|
c)
|
Initial notification/amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description of the financial
instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W1053
|
b)
|
Nature of the transaction
|
Increase in interest in American Depository Shares following the
re-investment of dividends paid to shareholders on 11 April 2019 on
American Depository Shares held in the Company's Deferred Annual
Bonus Plan.
|
c)
|
Price(s) and
volume(s)
|
Price(s)
|
Volume(s)
|
$
40.9400
|
538.000
|
d)
|
Aggregated information
Aggregated volume
Price
|
n/a (single transaction)
|
e)
|
Date
of the transaction
|
2019-04-12
|
f)
|
Place of the
transaction
|
New York Stock Exchange (XNYS)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Mr R G Connor
|
b)
|
Position/status
|
President, Global Vaccines
|
c)
|
Initial
notification/amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description of the
financial instrument
|
Ordinary shares of 25 pence each ('Ordinary
Shares')
ISIN: GB0009252882
|
b)
|
Nature of the
transaction
|
Increase in interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 11 April 2019 on Ordinary
Shares held in the Company's Deferred Annual Bonus
Plan.
|
c)
|
Price(s) and
volume(s)
|
Price(s)
|
Volume(s)
|
£15.6560
|
238.000
|
£15.6560
|
135.000
|
£15.6560
|
193.000
|
£15.6560
|
135.000
|
d)
|
Aggregated
information
Aggregated volume
Price
|
701.000
£15.6560
|
e)
|
Date
of the transaction
|
2019-04-12
|
f)
|
Place of the
transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Mr S P Dingemans
|
b)
|
Position/status
|
Executive Director
|
c)
|
Initial
notification/amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description of the
financial instrument
|
Ordinary shares of 25 pence each ('Ordinary
Shares')
ISIN: GB0009252882
|
b)
|
Nature of the
transaction
|
Increase in interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 11 April 2019 on Ordinary
Shares held in the Company's Deferred Annual Bonus
Plan.
|
c)
|
Price(s) and
volume(s)
|
Price(s)
|
Volume(s)
|
£15.6560
|
649.000
|
£15.6560
|
236.000
|
£15.6560
|
645.000
|
£15.6560
|
236.000
|
d)
|
Aggregated
information
Aggregated volume
Price
|
1766.000
£15.6560
|
e)
|
Date
of the transaction
|
2019-04-12
|
f)
|
Place of the
transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Mr J Ford
|
b)
|
Position/status
|
SVP and General Counsel
|
c)
|
Initial
notification/amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description of the
financial instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W1053
|
b)
|
Nature of the
transaction
|
Increase in interest in American Depository Shares following the
re-investment of dividends paid to shareholders on 11 April 2019 on
American Depository Shares held in the Company's Deferred Annual
Bonus Plan.
|
c)
|
Price(s) and
volume(s)
|
Price(s)
|
Volume(s)
|
$
40.9400
|
46.000
|
d)
|
Aggregated
information
Aggregated volume
Price
|
n/a (single transaction)
|
e)
|
Date
of the transaction
|
2019-04-12
|
f)
|
Place of the
transaction
|
New York Stock Exchange (XNYS)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Mr N Hirons
|
b)
|
Position/status
|
SVP, Global Ethics & Compliance
|
c)
|
Initial
notification/amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description of the
financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
b)
|
Nature of the
transaction
|
Increase in interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 11 April 2019 on Ordinary
Shares held in the Company's Deferred Annual Bonus
Plan.
|
c)
|
Price(s) and
volume(s)
|
Price(s)
|
Volume(s)
|
£15.6560
|
99.000
|
£15.6560
|
85.000
|
£15.6560
|
101.000
|
£15.6560
|
85.000
|
d)
|
Aggregated
information
Aggregated volume
Price
|
370.000
£15.6560
|
e)
|
Date
of the transaction
|
2019-04-12
|
f)
|
Place of the
transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Mr B McNamara
|
b)
|
Position/status
|
CEO, GSK Consumer Healthcare
|
c)
|
Initial
notification/amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description of the
financial instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W1053
|
b)
|
Nature of the
transaction
|
Increase in interest in American Depository Shares following the
re-investment of dividends paid to shareholders on 11 April 2019 on
American Depository Shares held in the Company's Deferred Annual
Bonus Plan.
|
c)
|
Price(s) and
volume(s)
|
Price(s)
|
Volume(s)
|
$
40.9400
|
90.000
|
$
40.9400
|
98.000
|
$
40.9400
|
96.000
|
d)
|
Aggregated
information
Aggregated volume
Price
|
284.000
$ 40.9400
|
e)
|
Date
of the transaction
|
2019-04-12
|
f)
|
Place of the
transaction
|
New York Stock Exchange (XNYS)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Mr L Miels
|
b)
|
Position/status
|
President, Global Pharmaceuticals
|
c)
|
Initial
notification/amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description of the
financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
b)
|
Nature of the
transaction
|
Increase in interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 11 April 2019 on Ordinary
Shares held in the Company's Deferred Annual Bonus
Plan.
|
c)
|
Price(s) and
volume(s)
|
Price(s)
|
Volume(s)
|
£15.6560
|
253.000
|
£15.6560
|
183.000
|
d)
|
Aggregated
information
Aggregated volume
Price
|
436.000£15.6560
|
e)
|
Date
of the transaction
|
2019-04-12
|
f)
|
Place of the
transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Mr D Redfern
|
b)
|
Position/status
|
Chief Strategy Officer
|
c)
|
Initial
notification/amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description of the
financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
b)
|
Nature of the
transaction
|
Increase in interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 11 April 2019 on Ordinary
Shares held in the Company's Deferred Annual Bonus
Plan.
|
c)
|
Price(s) and
volume(s)
|
Price(s)
|
Volume(s)
|
£15.6560
|
225.000
|
£15.6560
|
107.000
|
£15.6560
|
187.000
|
£15.6560
|
107.000
|
d)
|
Aggregated
information
Aggregated volume
Price
|
626.000
£15.6560
|
e)
|
Date
of the transaction
|
2019-04-12
|
f)
|
Place of the
transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Mr R Simard
|
b)
|
Position/status
|
President, Pharmaceuticals Supply Chain
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description of the
financial instrument
|
Ordinary shares of 25 pence each ('Ordinary
Shares')
ISIN: GB0009252882
|
b)
|
Nature of the
transaction
|
Increase in interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 11 April 2019 on Ordinary
Shares held in the Company's Deferred Annual Bonus
Plan.
|
c)
|
Price(s) and
volume(s)
|
Price(s)
|
Volume(s)
|
£15.6560
|
81.000
|
d)
|
Aggregated
information
Aggregated
volume
Price
|
n/a (single transaction)
|
e)
|
Date
of the transaction
|
2019-04-12
|
f)
|
Place of the
transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Ms K Terrell
|
b)
|
Position/status
|
Chief Digital & Technology Officer
|
c)
|
Initial
notification/amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description of the
financial instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W1053
|
b)
|
Nature of the
transaction
|
Increase in interest in American Depository Shares following the
re-investment of dividends paid to shareholders on 11 April 2019 on
American Depository Shares held in the Company's Deferred Annual
Bonus Plan.
|
c)
|
Price(s) and
volume(s)
|
Price(s)
|
Volume(s)
|
$
40.9400
|
114.000
|
$
40.9400
|
32.000
|
d)
|
Aggregated
information
Aggregated volume
Price
|
146.000
$ 40.9400
|
e)
|
Date
of the transaction
|
2019-04-12
|
f)
|
Place of the
transaction
|
New York Stock Exchange (XNYS)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Mr P C Thomson
|
b)
|
Position/status
|
President, Global Affairs
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description of the
financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
b)
|
Nature of the
transaction
|
Increase in interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 11 April 2019 on Ordinary
Shares held in the Company's Deferred Annual Bonus
Plan.
|
c)
|
Price(s) and
volume(s)
|
Price(s)
|
Volume(s)
|
£15.6560
|
131.000
|
£15.6560
|
102.000
|
£15.6560
|
126.000
|
d)
|
Aggregated
information
Aggregated volume
Price
|
359.000
£15.6560
|
e)
|
Date
of the transaction
|
2019-04-12
|
f)
|
Place of the
transaction
|
London Stock Exchange (XLON)
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
GlaxoSmithKline plc
|
|
(Registrant)
|
|
|
Date: April
16, 2019
|
|
|
|
|
By: VICTORIA
WHYTE
--------------------------
|
|
|
|
Victoria Whyte
|
|
Authorised
Signatory for and on
|
|
behalf
of GlaxoSmithKline plc
|
GSK (NYSE:GSK)
Historical Stock Chart
From Aug 2024 to Sep 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Sep 2023 to Sep 2024